Advertisement

Topics

Orbsen gets European approval to start diabetic kidney disease trial for Obrcel-M

04:59 EDT 3 Aug 2017 | Pharmaceutical Business Review

Orbsen Therapeutics’ stromal cell immunotherapy, OBRCEL-M has been approved to begin testing in a randomised, double blind, and placebo-controlled clinical trial in Europe to treat diabetic kidney disease.

Original Article: Orbsen gets European approval to start diabetic kidney disease trial for Obrcel-M

NEXT ARTICLE

More From BioPortfolio on "Orbsen gets European approval to start diabetic kidney disease trial for Obrcel-M"

Quick Search
Advertisement
 

Relevant Topics

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...